Athersys ATHX today announced positive interim results from an ongoing Phase I clinical trial of
MultiStem^®, its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants for the treatment of leukemia and related conditions. The study results for the single infusion arm
of this Phase I clinical trial demonstrate that MultiStem was well tolerated at all dose levels and also suggest that the product may reduce the incidence of severe Graft-versus-Host Disease a potentially life-threatening
complication of such transplants, as compared to historical clinical experience. The repeated dose administration arm of the clinical trial is ongoing and enrollment is expected to be completed in 2011. In 2010, Athersys
was granted orphan drug designation by the U. S. Food and Drug Administration for MultiStem for the prevention of GvHD.
Interim data highlights from the single dose administration arm of the study included:
* No observations of infusional or product-related toxicities over 30 days
following treatment, and no product-related serious adverse events (SAEs)
over 100 days following treatment;
* No primary or secondary HSCT-graft failure through day 100;
* Overall, a low cumulative incidence of acute GvHD over the 100-day
observation period for all subjects enrolled (28% grade II-IV, 6% grade
III-IV), which compares favorably with expectations for this patient
population based on historical experience;
* In the high dose group, no cases of grade III-IV GvHD, and only one case
of grade II GvHD, which was subsequently resolved with treatment; and
* Other clinical parameters, such as infection and survival, were in line
with or better than expectations for this patient population based on
historical data.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in